Multi-Omics Integration: Diabetic Heart Disease Drivers

Heart failure in type 2 diabetes often arrives with open coronary arteries and a stiff, poorly relaxing left ventricle, and the molecular reasons have stayed murky in actual human myocardium. A new study in Genome Medicine used multi-omics integration to profile left ventricular tissue from people with diabetic cardiomyopathy, set against non-diabetic cardiomyopathy and healthy donor hearts. The team paired RNA sequencing, 4D-DIA proteomics, and full-spectrum metabolite profiling on the same samples, then checked the leading signals against public datasets and mouse models. What surfaced was not one broken pathway but three that fail together.

What Multi-Omics Integration Showed in Diabetic Hearts

Left ventricular samples came from matched Chinese cohorts: 11 diabetic cardiomyopathy hearts, 11 non-diabetic cardiomyopathy hearts, and 4 healthy donors. Across the proteomic and transcriptomic layers, the diabetic hearts carried a rewired fatty acid oxidation program, with acyl-CoA synthetase long-chain member 1 (ACSL1) raised and fatty acid synthase (FASN) pushed down. Mass spectrometry-based proteomics flagged a sharp drop in the mitophagy regulator BNIP3L, and its levels tracked inversely with ACSL1 across patients. As Boudina and Abel (2007) argued years ago, the diabetic heart burns fat under duress; the metabolite profiling here shows depleted triglycerides alongside a backlog of acylcarnitines and lipotoxic lipids. Structural genes for the extracellular matrix, including COL5A1, COL5A2, and fibrillin-1, were selectively lower.

Key Findings

• A rewired fuel-handling axis: ACSL1 rose while FASN fell, marking a shift toward fatty acid import and oxidation over synthesis in diabetic myocardium.

• Mitophagy fails at a single node: BNIP3L, a core mitophagy regulator, dropped sharply and correlated inversely with ACSL1, tying weak mitochondrial cleanup to lipid overload.

• The matrix thins selectively: COL5A1, COL5A2, and fibrillin-1 were downregulated, pointing to extracellular matrix remodeling alongside the metabolic shift.

• Oxidation that never finishes: metabolomics showed triglyceride depletion with accumulating acylcarnitines, a signature of enhanced but incomplete fatty acid oxidation.

Figure 1. Multi-omics landscape of the diabetic human heart. Panels A to C show multivariate score plots for the transcriptomic, proteomic, and metabolomic layers, separating diabetic cardiomyopathy, non-diabetic cardiomyopathy, and healthy donor hearts. Panel D maps differentially abundant features across the three pairwise comparisons, and Panel E gives a Venn diagram of their overlap. Panel F shows pathway enrichment across discovery and validation sets, with dot size scaled to significance and color to enrichment score. Panels G to O quantify selected pathway and molecular markers across groups. Adapted from Lu et al. (2026), Genome Medicine.

Following the Fatty Acid Oxidation to Mitophagy Axis

The clearest molecular thread runs from how these hearts source fuel to how they clear worn-out mitochondria. Elevated ACSL1 channels free fatty acids into mitochondria for oxidation, while suppressed FASN signals a retreat from lipid synthesis. With BNIP3L low, damaged mitochondria are not cleared efficiently, so the cell keeps feeding fat into organelles that can no longer keep up. The authors support the link with western blotting and histology.

Matrix Remodeling and the Limits of the Cohort

Beyond metabolism, the diabetic hearts showed a quieter loss of structural integrity. Collagen V chains and fibrillin-1, which organize the fibrillar matrix, were consistently downregulated, a pattern that fits the stiff-yet-fragile mechanics seen in diabetic cardiomyopathy. One caution is worth stating plainly: with only four healthy donor hearts, the reference arm is thin, and several effect sizes will need a larger cohort before anyone builds a diagnostic around them.

Reading Three Layers From One Heart Sample

Pulling transcriptomic, proteomic, and metabolite signals from the same scarce myocardial biopsy is what lets the BNIP3L-ACSL1 link read as one coherent story rather than three loosely stitched datasets. When each layer comes off a separate aliquot, batch structure and tissue heterogeneity can blur exactly the cross-layer correlations this paper leans on. We hit the same wall in client work at Dalton, which is why the Omni-MS workflow measures proteins and metabolites from a single injection of one sample, keeping the layers anchored to the same biology.

Frequently Asked Questions

What is multi-omics integration?

Multi-omics integration combines data from two or more molecular layers, such as transcriptomics, proteomics, and metabolomics, into one analysis. Signals that agree across layers are usually more credible than a hit seen in a single dataset.

What did multi-omics integration reveal about diabetic cardiomyopathy?

It showed that diabetic human hearts dysregulate fuel metabolism, mitochondrial quality control, and matrix structure at once. The analysis flagged elevated ACSL1 and suppressed BNIP3L as a coupled node and candidate therapeutic targets.

How many samples does a multi-omics cardiac study typically use?

Human myocardial studies often run on small numbers because tissue is hard to obtain; this one used 26 hearts across three groups. Small cohorts can still generate strong leads when several omics layers agree, though larger validation is needed before clinical use.

Conclusion

The case that diabetes reshapes cardiac fuel use, mitochondrial cleanup, and matrix structure together, rather than as separate hits, now looks reasonably solid in human tissue. Causality isn't settled, the donor numbers are small, and the mouse data are supportive rather than decisive. For target hunters, ACSL1 and BNIP3L are worth a closer look before they reach a screening deck.

Citation

Lu, Q., Tang, S., Fang, S., Wu, Y., Chen, L., Liang, M., Chen, J., Wen, P., Jin, L., Yu, J., Jiao, F., Wu, Y., & Jiang, G. (2026). Multi-omics profiling of the diabetic human heart reveals coupled dysregulation in lipid metabolism, mitophagy, and extracellular matrix remodeling. Genome Medicine, 18. https://doi.org/10.1186/s13073-026-01668-0

Note

This blog post summarizes findings from the above-cited research. Figures are adapted from the original publication. For full details, please refer to the source article.

By Seungjun Yeo, Co-Founder and CEO at Dalton Bioanalytics. Specializing in multi-omics mass spectrometry for drug discovery and biomarker research.